Synagis (Palivizumab Vials) 100mg/ml

Palivizumab (SYNAGIS) is a monoclonal antibody used to help prevent serious lung infections caused by respiratory syncytial virus (RSV) in high-risk infants. This 100mg/ml vial formulation is designed for intramuscular injection. Store between 2-8°C to maintain potency and efficacy.

Strength

100mg/ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Astrazeneca

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Palivizumab (SYNAGIS) is prescribed to reduce the risk of RSV-related hospitalizations in premature infants and children with specific heart or lung conditions. It is not a vaccine but provides passive immunity during RSV season. Parents often ask what is palivizumab used for when discussing RSV prevention strategies with pediatricians.

Side Effects

Many patients experience no noticeable effects after receiving palivizumab injections. Some infants may experience mild redness or swelling at the injection site. Temporary fussiness or low-grade fever occasionally occurs but typically resolves quickly.

Precautions & Warnings

Keep palivizumab vials refrigerated between 2-8°C and protect from light until ready for use. Do not freeze or shake the vial vigorously. Always use sterile technique when preparing the dose. Discard any unused medication after the recommended administration period.

Avoid Interactions

Palivizumab has a low potential for drug interactions due to its targeted mechanism. No specific interactions with vaccines or other medications have been established. Always inform healthcare providers about all medications being administered to the infant.

Frequently Asked Questions

Palivizumab helps prevent serious respiratory infections caused by respiratory syncytial virus (RSV) in high-risk infants.

It is given as an intramuscular injection, typically once per month during RSV season.

Palivizumab is primarily approved for infants and young children at high risk for RSV complications.

Mild injection site reactions or temporary fussiness may occur but are generally short-lived.

Store vials refrigerated between 2-8°C and protect from light until time of use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.